BioCentury
ARTICLE | Company News

Cornerstone Therapeutics, Merus Labs International sales and marketing update

March 12, 2012 7:00 AM UTC

Merus acquired North American rights to Factive gemifloxacin mesylate from Cornerstone. Cornerstone will receive an undisclosed payment from Merus. Cornerstone said in its 2011 10-K that it is moving...